×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
MSN
Exelixis, Inc. EXEL entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx (cabozantinib).
14 hours ago
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Business Wire
Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and...
1 day ago
Exelixis announcess settlement of cabozantinib patent litigation with Cipla - TipRanks.com
Tipranks
Exelixis announced that it has entered into a Settlement and License Agreement with Cipl and Cipla USA, . This settlement resolves two...
18 hours ago
Exelixis reaches Cabometyx patent settlement with Cipla
Seeking Alpha
Exelixis reaches agreement with Cipla for marketing of generic Cabometyx, pending regulatory review. Read more here.
1 day ago
Exelixis maintains Outperform rating on recent settlement announcement
Investing.com
On Monday, Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company, received continued support from BMO Capital Markets following a recent...
1 day ago
July 19th Options Now Available For Exelixis (EXEL)
Nasdaq
Investors in Exelixis Inc (Symbol: EXEL) saw new options begin trading today, for the July 19th expiration. At Stock Options Channel,...
4 days ago
Quadrant Capital Group LLC Buys 750 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Defense World
Read Quadrant Capital Group LLC Buys 750 Shares of Exelixis, Inc. (NASDAQ:EXEL) at Defense World.
24 hours ago
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
The Motley Fool
During the first quarter of 2024, we repurchased approximately $191 million of Exelixis shares at an average price of $22.8. We remain committed...
3 weeks ago
Exelixis lays off 175 employees in refocus on 'emerging pipeline'
Fierce Biotech
The stream of new year layoffs shows no sign of abating, with Exelixis announcing that around 175 of its staff will heading for the exits.
4 months ago
Exelixis settles patent litigation with Cipla over CABOMETYX
Investing.com
ALAMEDA, Calif. - Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company, announced today that it has reached a settlement agreement with...
1 day ago